
Screened
N = 994
Screen Failures
N = 219
De Novo
N = 508
Rollover
BUP-XR 300/100 mg
N = 119
Rollover
BUP-XR 300/300 mg
N = 115
Placebo
N = 33
RUN-IN
Run-in Failures (N=96)
Withdrew consent 22
Adverse event 1
Lost to follow-up 44
Withdrawn by investigator 7
Protocol violation 2
Withdrawal Symptoms 1
Other 19
Run-in Failures (N=7)
Withdrew consent 3
Adverse event 1
Lost to follow-up 2
Withdrawn by investigator 1
Run-in Failures (N=2)
Lost to follow-up 1
Physician Decision 1
Run-in Failures (N=1)
Other 1
De Novo
N = 412
Rollover
BUP-XR 300/100 mg
N = 112
Rollover
BUP-XR 300/300 mg
N = 113
Placebo
N = 32
TREATMENT
Discontinued (N=206)
Withdrew consent 67
Adverse event 11
Lost to follow-up 80
Withdrawn by investigator 7
Protocol violation 4
Withdrawal Symptoms 3
Physician Decision 5
Other 28
Discontinued (N=18)
Withdrew consent 7
Lost to follow-up 9
Protocol violation 2
Discontinued (N=33)
Withdrew consent 14
Adverse event 3
Lost to follow-up 8
Withdrawn by investigator 1
Protocol violation 2
Other 5
Discontinued (N=6)
Withdrew consent 3
Adverse event 1
Lost to follow-up 2
De Novo
N = 206
Rollover
BUP-XR 300/100 mg
N = 94
Rollover
BUP-XR 300/300 mg
N = 80
Placebo
N = 26
COMPLETED